INTERNATIONAL JOURNAL OF CURRENT ADVANCED RESEARCH
ISSN: O: 2319-6475, ISSN: P: 2319-6505, Impact Factor: 6.614
Available Online at www.journalijcar.org
Volume 13; Issue 03; March 2024; Page No.2959-2969
DOI: http://dx.doi.org/10.24327/ijcar.2024.2969.1643

Research Article

IMMUNE CHECKPOINT BLOCKERS: CHALLENGES, OPPORTUNITIES AND STRATEGIES FOR CANCER PATIENTS

***Ashish Shivram Ramteke**

Visvesvaraya National Institute of Technology, Nagpur 440 010, India

ARTICLE INFO

Article History:
Received 14th February, 2023
Received in revised form 28th February, 2024
Accepted 13th March, 2024
Published online 28th March, 2024

Key words:
Checkpoints, Immunotherapy, Lymphocytes, Antibody, Cancer

ABSTRACT

The treatment of cancers with immune checkpoint blockers has been an important revolution in the area of cancer immunology. Advance medication strategy with the implementation of checkpoints blockers predicted that immunologists will deal with new challenges to control the adverse side effects related with the use of these drugs. They also accredit the require for taking a comprehensive reach to the patient, which is a principle broadly acknowledged in oncology and mainly specific in the trial of the extending use of immune checkpoint inhibitors, which can give increase to a broad variety of organ issues arising from treatment. Understanding and attention of the spectrum of immune-related adverse events will permit immunologists to select patients for medication more sophisticated, prevent problems, truth-worthy detected, and finally treat them. There is a crucial requirement for interdisciplinary collaboration in the cancer treatment undergoing immunotherapy and experiencing the subsequent adverse reactions to treatment.

INTRODUCTION

Immune checkpoints blockers (anti-CTLA-4, anti-PD-1/PD-L1) can comprise an innovation in terms of an advance immunotherapy in the cancer treatment as they have provided to development in the patient's expectation with neoplasms like renal cell carcinoma, melanoma, non-small cell lung cancer (NSCLC), urothelial carcinoma, head and neck squamous cell cancer (HNSCC), and Hodgkin's lymphoma (lymphatic system).[1] Although, it is only viable to believe that patients and doctors will have to resist with a broad spectrum of immune related adverse events related with the treatment. Connection with these non-spontaneous problems, will be the revoke of immunologists due to the possibility that particular organs will be affected, means it is probable to increased also to specialists in different areas of internal medicine.[2]

In addition, patients with more non-specific indications would be predicted, to argue their common professionals. Hence, the several treatment efficacies will depend on the primary conclusions taken with respect to their demonstration. The most quickly recorded common indications are weakness and fatigue, can be a direct outcome of anti-PD-1/anti-CTLA-4 immunotherapy, but can also be an indication of endocrinopathy (hypothyroidism)[3], or even a progression symptom of the hidden disease. Case reports and clinical trials assist to remember us that adverse effects can develop at any stage of treatment or many weeks after its completion, when the patient is unsecure to oncological observation.[4]

Carcinogenesis and immune control mechanism

Cancer cells may initiate resistance to the mechanisms of the immune system, hence achieving the rational of abnormal progression. This situation may be elaborated in terms of cancer immunoediting hypothesis, which resists that transformed cells can disappear in the last phase of a process of control involving of three phases (elimination, equilibrium, and escape) and which contains a particular form of immune surveillance of cancer cells.[5] First phase involves suppressor mechanisms underline and eliminate creating cancers before they become clinically visible. After that is equilibrium phase of cancer dormancy, in which the cancer and immune cells are brought into a dynamic equilibrium that maintain the evolution of the cancer.[6] Eventually, escape denotes the point of cancer cells appearance, which either display lowered immunogenicity or activate a huge number of potential immunosuppressive actions that decrease the anticancer immune response, causing to the emergence of progressively initiating cancers.[7]

Immunotherapy has a well-settled frame in the treatment of cancer patients, (generally melanoma). Although further investigations have not illustrated the expected outcomes, present records and experience linked with the use of interleukin-2 (IL-2) or interferon-α (INF-α) have reported the possible advantages that can be gained in patients treated with therapies regulating the immune response. Presently, impressive growth in cancer biology has been found as a result of the broad presentation of immunotherapy.[8] Moreover, raising numbers of modern antibodies are under clinical trials,

Corresponding author:* **Ashish Shivram Ramteke
Visvesvaraya National Institute of Technology, Nagpur 440 010, India

and those already in ongoing are achieving a broader range of significance. Over a time of 2017 to 2019, a rise in the number of functional agents of around 91 %, a 78 % rise in active immuno-oncology targets, and a 60 % increase in participating institutions were reported. The number of T-cell regulators are used in clinical trials increased from 332 to 620 (in years 2017-2019).[9]

There may some confusion about progressively cancer patients globally will be introduced immunotherapy (ICIs) divided through action mechanism used in regular clinical settings and treatment (**Table 1**). This type of modern drugs impacting the patient's immunity produce a challenge to immunologists and also medical practitioner, who will automatically come into events with the adverse difficulties caused through this medication. Furthermore, immunologists themselves are probable to covert to doctor's help and support in these new challenges.[10]

PD-1 receptor and its role in cancer

Activation of lymphocytes needs particular recognition pattern of the antigen displayed and a signal from co-stimulators that are assembled during the formation of an immune synapse. Co-stimulators on the surface of lymphocytes can involve the CD28 cell differentiation antigens family. Negative cell receptors are molecules that create an inhibiting signal to cell effector functions.[11] This mechanism is planned to resist the undesirable events of overstimulation and eventually lead an autoreactive response or carcinogenesis provoke once the protective role of the lymphocyte antigen is aborted. This receptor is the PD-1 (CD279) which a member of the B7 (CD28) family.[12] The transmembrane glycoprotein is presented on activated T-cell, B-cell, natural killer (NK) cells, and monocytes. PD-1 has structurally a cytoplasmic tail with two tyrosine kinase residues cause for inhibitory signaling, whilst the PD-1 expression during antigen stimulation is support on the signaling pathway of the T-cell (TCR) and B-cell (BCR) receptor.[13]

PD-1 activation bears on binding to related ligands: PD-L1 or PD-L2. While one of them is displayed on the surface of APCs, involving dendritic bears that PD-L1 is generally reasonable for the suppressive effect. It has been concluded that anti-PD-1 blocking drugs have a higher efficacy for ligands than activated T-cells.[14] The activation of PD-1 receptor through ligand signaling, the negative feedback mechanism causes to TCR/BCR block and a decrease in the intensity of cytokine production (IL-10). Furthermore, improvement of p15 protein expression resists G_1 phase transition or SKP2 transcription. This gene is manageable for the coding of the protein component of ubiquitin ligase to degrades the p27 cancer suppressor.[15] During longer antigenic stimulation (chronic viral infections or carcinogenesis), PD-1 overexpression causes to the T-cell phenotype determined as "exhausted". They functions are inactivated and hence lowers proliferation and capacity to liberate interferon γ (IFN-γ) causing to cytotoxicity (**Fig. 1**).[16]

The PD-L1 expression on the cell surface of several cancers has been illustrated and investigated that it is a negative prognostic factor in patients with melanoma, renal cell carcinoma, breast, lung, stomach, pancreas, liver, and bladder cancer. PD-L1 over expression on the cancer surface is not always linked with a poor prognosis. Importantly, increased rates of survival in melanoma patients with PD-L1 exposure lymphocytes makes it eligible to create their function was moderated because of the reaction with neoplastic cells through anticancer IFN-γ.[17]



Fig. 1 PD-1/PD-L1 and its blockers' role in T-cell activation

Therefore, the PD-1/PD-L1 pathways participation as an obtained cancer adaptation mechanism is feasible towards sign of resistance to the body's defensive mechanisms. Blocking of PD-1/PD-L1 function presents to refurbishment of T-cell function and enhances the $CD8^+$ T-cells penetration in a mouse model of pancreatic cancer.[18] These having a symbiotic effect with chemotherapy and resisting the spread of melanoma and colorectal cancer in mice. Hence, it can be summarized that antibodies inhibiting the PD-1/PD-L1 pathway would develop to give suitable signs for boosting the efficaciousness of immunotherapy in cancer patients.[19]

Anti-PD-1 antibodies in cancer immunotherapy

Nivolumab

Nivolumab, a human IgG_4a monoclonal antibody that was authorized through FDA (2014) for monotherapy in advanced or unresectable cancer patients. From several clinical trials, the symptoms were developed among others to involve patients with the BRAF V600 mutation, since illustrated disease progression after treatment with specific inhibitors.[20] Combined therapy nivolumab with ipilimumab was authorized as use in adjuvant treatment after proper surgical procedure in patients. In cutaneous melanoma the further advantages of nivolumab treatment over specific chemotherapy regimens have been evaluated.[21] Nivolumab monotherapy was seen to be more impressive than recognized docetaxel chemotherapy in producing an objective response rate (ORR) (20 % vs 9 %), progression free survival (PFS) and overall survival (OS) with an importantly reduce rate of G≥3 adverse events (10 % vs 54 %). Nivolumab nearly doubles the evaluated a year survival in patients introduced for metastatic HNSCC after chemotherapy with platinum derivatives as compared to particular drugs employed in secondary treatment (docetaxel, methotrexate or cetuximab).[22]

Nivolumab monotherapy has seen to bring important clinical advantages, assisted with a possible protection profile in patients with advanced or unresectable bladder cancer after undergone chemotherapy. Prolonged responses to treatment and overall survival extension were the basis for the authorize of nivolumab for the treatment of patients with advanced renal cell carcinoma after early anti-angiogenic treatment.[23] Nivolumab is also a fascinating therapeutic strategy for patients with advanced colorectal cancer with MMR or MSI deficiency. While this patient has a lower prognosis and response to possible treatment, but recently collected records are not enough to extend access to nivolumab for these patients, especially for women with advanced ovarian cancer

against to platinum chemotherapy.[24] Nivolumab has been implemented in the treatment of solid cancers as well as patients with lapsed or refractory Hodgkin's lymphoma. An investigation demonstrated an increase ORR of patients gained a complete response (87 % and 17 %), with a slowly rises percentage of patients with complications (≥3 degree) compared to patients administered with nivolumab for solid cancers.[25]

Pembrolizumab

Such as nivolumab, pembrolizumab is a humanized antibody that affiliated with the IgG_4a family. Clinical records have seen that patients treated with advanced cutaneous melanoma advantage importantly from treatment with pembrolizumab (response rates, PFS and OS).

Table 1 Immune checkpoint blockers to their mechanism and diseases treated

ICB	Drugs	Disease
CTLA-4 blockers	Ipilimumab Tremelimumab	Melanoma Melanoma, mesothelioma, NSCLC
PD-1 blockers	Nivolumab Pembrolizumab Pidilizumab Cemiplimab	Melanoma, NSCLC, HNSCC, bladder cancer, renal cell carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, stomach & esophagus cancer, squamous cell carcinoma Melanoma, NSCLC, bladder cancer, HNSCC, Hodgkin lymphoma, stomach & esophagus cancer, squamous cell carcinoma B-cell lymphoma, follicular lymphoma, multiple myeloma Squamous cell carcinoma
PD-L1 blockers	Atezolizumab Durvalumab Avelumab	Bladder cancer, HSCLC NSCLC, urothelial cancer Merkel cell carcinoma
Combined therapy	Ipilimumab plus nivolumab Durvalumab plus tremelimumab	Melanoma, renal cell carcinoma, stomach cancer, esophagus cancer Lung cancer, bladder cancer, HCC, head & neck cancer

Table 2 National Cancer Institute's grades for adverse events

Grade 1 (G_1)	Grade 2 (G_2)	Grade 3 (G_3)	Grade 4 (G_4)
Hypothyroidism Asymptomatic; clinical or diagnostic observations; intervention not indicated	Symptomatic; thyroid replacement indicated; limiting instrumental ADL	Severe symptoms; limiting self-care ADL; hospitalization indicated	Life-threatening consequences; urgent intervention indicated
Hyperthyroidism Asymptomatic; clinical or diagnostic observations only; intervention not indicated	Asymptomatic; clinical or diagnostic observations only; intervention not indicated	Severe symptoms; limiting self-care ADL; hospitalization indication	Life-threatening consequences; urgent intervention indication
Adrenal insufficiency Asymptomatic; clinical or diagnostic observations only; intervention not indicated	Moderate symptoms; medical intervention indicated	Severe symptoms; hospitalization indicated	Life-threatening consequences; urgent intervention indicated
Colitis Asymptomatic; clinical or diagnostic observations only; intervention not indicated	Abdominal pain; mucus or blood in stool	Severe abdominal pain; peritoneal signs	Life-threatening consequences; urgent intervention indicated
Pneumonitis Asymptomatic; clinical or diagnostic observations only; intervention not indicated	Symptomatic; medical intervention indicated; limiting instrumental ADL	Severe symptoms; limiting self-care ADL, oxygen indicated	Life-threatening respiratory compromise; urgent intervention indicated

Table 3 Adverse events of patient's endocrine system treated with immunotherapy

Organ	Symptoms	Diagnostic outcomes	Suspected pathology
Thyroid	Fatigue Weight gain Hair loss Constipation Depression Weight loss Weakness	High TSH Low fT_4 Low T_3 Hyponatremia Hypercalcemia Low TSH Thyroid stimulating IG	Primary hypothyroidism Primary hyperthyroidism
Pituitary	Headache Fatigue Nausea Hypotension	Low TSH Low fT_4 Harmone deficiencies Low cortisol	Hyphophysitis
Adrenal gland	Weakness Appetite loss Muscle pain Fatigue Hyperpigmentation	Hyponatremia Hyperkaliemia Hypoglycemia Hypercalcemia High ACTH	Primary adrenal insufficiency
Pancreatic β-cells	Polyuria Nausea Ketoacidosis	Glucose level Low C-peptide Antibodies test	Diabetes type I

Table 4 Incidence of endocrinopathy in various clinical trials with immunotherapy

Adverse Events	Anti-PD-1/PD-L1	Anti-CTLA-4	Combined therapy
Thyroid dysfunction	5.0-19 %	1.0-15.2 %	15-50 %
Hypothyroidism	7.0-8.6 %	2.8-4.2 %	13.2-16.4 %
Hyperthyroidism	3.0-3.3 %	0.6-0.9 %	8.0-11.1 %
Hypophysitis	0.4-0.7 %	1.0-17 %	7.7-11.7 %

Pembrolizumab is also used in the primary treatment of patients with metastatic, NSCLC, EGFR and ALK mutations as well as a level of neoplastic cells with PD-L1 expression in neoplastic tissue (50 %).[26] Patients with an unresponsive to platinum-based chemotherapy or targeted therapy in patients with EGFR or ALK mutations, pembrolizumab may be used as the secondary treatment. Pembrolizumab monotherapy is reported in the treatment with generally advanced or metastatic bladder cancer after difficulty of platinum-based chemotherapy approves for a statistically possible extension of OS compared to standard secondary chemotherapy regimens.[27] Pembrolizumab may be used in Hodgkin's lymphoma patients after autologous bone marrow transplantation and brentuximab therapy or when transplantation is impossible and the patient has unresponsive to treatment with brentuximab.[28]

Pidilizumab and Cemiplimab

Pidilizumab is the first anti-PD-1 antibody to be implemented in cancer patients. It is a humanized, mouse IgG_1 antibody that produces strong antibody dependent cell mediated cytotoxicity (ADCC) activity. Investigations in mice have reported that T-cells and NK cells are required for the anticancer function to be satisfied.[29] Phase I and II investigations have been carried to estimate the efficiency of the treatment of DLBC after autologous stem cell transfer, lapsed FL and melanoma. The feasibility of curing patients with diffuse intrinsic pontine glioma in children and with lapsed multiple myeloma is presently being evaluated.[30] Cemiplimab is the first IgG_4 monoclonal antibody authorized in the USA and EU for use in patients with metastatic or advanced cutaneous squamous cell carcinoma (CSCC). While in clinical trials half of the patients replied to treatment, median value for OS and PFS were unreached during the experiments, which underlines clinically important treatment efficient and durability of responses.[31]

Anti-PD-L1 antibodies in cancer immunotherapy

Atezolizumab and Durvalumab

Atezolizumab, which is a humanized monoclonal antibody marked in monotherapy in advanced or disseminated bladder cancer after early platinum-based chemotherapy or with adverse condition for this class of cytostatic. It is also authorized for the treatment of patients with advanced or disseminated NSCLC after early chemotherapy or targeted treatment (on basis of EGFR or ALK mutation change).[32] Durvalumab is a human monoclonal antibody authorized for the treatment of patients with locally advanced, incurable NSCLC after radiochemotherapy. Recombined clinical trial was illustrated that the progression free time (17.2 vs 5.6 months) was increased almost threefold in patients cured with durvalumab compared to inactive drug. The FDA authorized durvalumab in 2017 through means of a quickened procedure for the treatment of patients with locally advanced or metastatic urothelial cancer who had achieved losses from platinum-based chemotherapy.[33]

Avelumab

Avelumab is a fully humanized antibody that creates a double effect to resists link of PD-L1 on a cancer cell with PD-1 on T-cells and has ADCC activity, which is introduced through binding to receptors on the effector immune cells. The capability of avelumab to boost ADCC has caused to a grant deal of investigations being processed into its mechanism of action and officiousness in the treatment of neoplastic diseases.[34] Avelumab has been authorized for the treatment of advanced MCC. The FDA has authorized avelumab as a secondary therapy after or during platinum chemotherapy in locally advanced or metastatic urothelial cancer. After illustrating an enhancement in PFS for avelumab with axitinib as compared to sunitinib (8.4 in sunitinib vs PFS 13.8 months) in renal cell carcinoma.[35]

CTLA-4 receptor and its role in cancer

The several of investigations of antibodies inhibiting the cytotoxic T-lymphocyte associate antigen 4 (CTLA-4) and hence boosting the immune response to the cancer cells have been successfully reported. Report produced in clinical trials of ipilimumab (anti-CTLA-4) were the based for the drug authorize in 2011 through the FDA in patients with clinically advanced melanoma. The CTLA-4 molecule is engaged from the cytoplasm to the T-cell effector membrane to become part of the two-phase immune synapse.[36] The primary signal is the identification of the antigen expressed through MHC class I or II on the surface of APCs through the TCR causes to a rise in the response of CD4 and CD8 receptors. The secondary signal essential for synapse produce is the co-stimulating CD80/CD86 molecules (B7-1 and B7-2) interaction on the surface of APCs with CD28 on the T-cells surface causes to the lymphocyte activation and differentiation.[37]

CTLA-4 engages with CD28 for binding to ligands on the APC cells with a higher affinity for B7 family ligands, besides replacing CD28 from connection with CD80/86. The binding of CTLA-4 to ligands (CD80-B7-1, CD86-B7-2) on APC cells reveals to the inducing of an inhibitory reaction suppression of the immune response through inhibiting the T-cell response, lowering the proliferation of T-cells, blocking the activity of Treg cells, and lowering cytokine production.[38] Furthermore, rise in levels of CTLA-4 expression cause to functional reprogramming of Th cells into regulatory T-cells which show strong immunosuppression. Activation, inhibition, and reactivation of T-cell through inhibiting CTLA-4 with anti-CTLA-4 blockers (ipilimumab, tremelimumab) are investigated (**Fig. 2**).[39]

Anti-CTLA-4 antibodies in cancer immunotherapy

Ipilimumab

Ipilimumab was the first anti-CTLA-4 antibody authorized through the FDA and assessed into clinical practice in cancer patients. It is a fully human IgG_1 monoclonal antibody that has been displayed to produce a long-term survival benefit in patients with advanced melanoma. Presently, awareness was supported to the beneficial extension of OS, beside a relatively small percentage of objective responses to treatment (nearly 10 %)[40] and the finite number of patients obtaining long-term advantages from the treatment (20-25 %).



Fig. 2 Activation, inhibition, and reactivation of T-cell through antibodies

Awareness was also outlined to the uncommon profile of adverse events during the trial of ipilimumab treatment (generally skin and gastrointestinal problems). Exploits with the implementation of anti-CTLA-4 therapy experienced to the significance that patients should be under multidisciplinary health care.[41]

Anti-CTLA-4 and anti-PD-1/PD-L1 combined immunotherapy

The combine blocking of both checkpoints has been the concern of investigated conducted nearly in parallel with the trial of single drugs into common use and is explained through the correspondent mechanisms of actions (**Fig. 3**). While the efficiency and toxicity outline of ipilimumab treatment was explored in the treatment direction of advanced cutaneous melanoma. The combined anti-CTLA-4 and anti-PD-1 treatment proposed unique problems in the treatment of adverse events.[42] It was showed that blocking both checkpoints created better clinical results than through the drugs trials in monotherapy. The objective response rate for the combined ipilimumab and nivolumab was 57.6 %, whilst for nivolumab monotherapy it was 43.7 %, in comparison to patients trialed with ipilimumab alone for advanced melanoma (19 %). Furthermore, the median PFS was 11.5 months, a beneficial enhancement against to ipilimumab monotherapy (2.9 months). The 2 years OS also recorded with combined therapy (64 %) verses nivolumab monotherapy (59 %) and for ipilimumab (45 %).[43]

Assumption for adverse events related with immunotherapy in malignancies

In the trial of monotherapy with nivolumab or ipilimumab, the incidence of adverse events was evaluated to develop in around 80 % of treated patients, these being commonly main signs of minor intensity. In the combined therapy, the incidence of adverse events raises to about 95 % with a crucial increase in the major percentage of $G_{3/4}$ adverse events (around 55 %). The most general were diarrhea (44.1 %), fatigue (35.1 %), and itching (33.2 %).[44] This raised inflexibility of adverse events is the price that patients are need to pay for enhancement in the outcomes of treatment assisted through the combined anti-CTLA-4 and anti-PD-1 in therapy.



Fig. 3 Immune checkpoint blocker's role in T-cell reactivation (A) Blocked T-cell functions in cancers (B) Checkpoint blockers reactivate T-cells

The rise in the incidence of adverse events in $G_{3/4}$ needs including not only from immunologists but also expertise in several areas. Because of their particular action profile, their toxicity is importantly variant from the adverse events of definitive chemotherapy.[45]

It should be reminded that these problems often intersect with the signs of chronic diseases or involve the incident of further various adverse events on the part of individual systems and organs. Because of the enormous spectrum of adverse events, their treatment needs the cooperation of multi-expertise groups. Drugs employed in the treatment of adverse events involve glucocorticosteroids, immunomodulating drugs for which exact procedural standards have been mentioned in the suggestions for their implementation.[46] Respective trials for adverse reactions are grouped according to 5 grades, providing on the inflexibility of signs: Grade 1 (G_1) for temperate, G_2 for moderate, G_3 for severe, G_4 for life-threatening, and G_5 for death. The most recurrent adverse events described in cancer patients undergoing therapy with ICIs are displayed according to their potency as distinguished through National Cancer Institute (**Table 2**).[47]

The first to emerge are generally skin symptoms (median 5.4 weeks from initiation), followed liver and gastrointestinal symptoms (median 7.4 weeks), and endocrine system symptoms (median 12.1 weeks). While as skin problems are occupied, they occur quite early and are recurrent, likewise is immunotherapy associated pneumonia which rises mostly at the starting phase of treatment (median 3.7 weeks), but with much reduce frequency and severity (a higher capability for this issue to develop has been presented in people trialed with immunotherapy because of non-squamous cell lung cancer).[48] In dual anti-PD-1 and anti-CTLA-4 therapy, signs of adverse events arise earlier and often with much intensity involving issues in the $G_{3/4}$ (54 %) against monotherapy (16-20 %). The combined ipilimumab and nivolumab causes to early treatment quit in around 30 % of patients. During monotherapy with anti-CTLA-4, more immune related adverse events (irAEs) are outlined compared to anti-PD-1.[49]

Assumption for the directions of endocrinopathy follow cancer therapy

Adverse events appearing from the endocrine system are to be predicted during the early 3 months of immunotherapy (**Table 3**). The incidence of endocrinopathy has been complicated to examine correctly because of various methods of diagnosis and recording used in different clinical trials (**Table 4**). Binding of a CTLA-4 blocker to particular endothelial cell surface receptors presented in the endocrine glands is linked with the initiation and stimulation of an autoimmune response.[50] Clinically beneficial endocrinopathy creates in less than 10 % of patients induced with CTLA-4 blockers, but in patients trialed with anti-PD-1/PD-L1, it bears to be maximum. Although pituitary inflammation is the most common problems related with anti-CTLA-4 treatment, distractions in thyroid function are recorded as the most general with anti-PD-1 treatment. Hyperthyroidism was monitored more quickly in patients introduced with anti-PD-1 than anti-CTLA-4 or anti-PD-L1.[51]

Patients should be actively observed for endocrine disease signs during treatment, but there can be instances when the patient display signs. Symptoms to which medical practitioners should be specifically aware involve raised heart rate and sweating, extreme tiredness or weakness, muscle pain, weight gain or loss, dizziness or fainting, unusual headache, blurred vision, hunger or thirst which varies from the norm, hair loss, feeling cold, and raised urination frequency.[52] This Autoimmune thyroid disease can present as primary hypothyroidism secondary to inflammation of the thyroid gland or hyperthyroidism related with Grave's disease. Fatigue, headache, and muscle weakness may be the clinical explanations of hypophysitis. These incidences of irAE are general in men and older patients, and can arise 6 to 12 weeks after initiation of immunotherapy.[53]
The diagnosis of pituitary incidences may be all the more problematic, moreover, applying steroid therapy to treat other irAEs, which can hide the symptoms of pituitary inflammation. Diagnosis depends on illustrating decrease levels of hormones secreted through the pituitary gland. It is valuable marking that hyponatremia can also occur, as it has been suddenly monitored in the case of pituitary inflammation during anti-CTLA-4 therapy.[54] This differentiates these types of irAEs from furthers, because the endocrine organ has already assisted damaged and several immunotherapies will not result in the reappearance of clinical signs if the hormones regarded are complemented. Treatment stop is only needed further endocrine disturbance episodes necessary hospitalization or in the case of life-threatening situations (adrenal insufficiency). Endocrinopathies, unlike adverse mechanisms in several organs or systems, can continue despite disruption or distraction of immunotherapy.[55]

Management and suggestions for adverse events in several medications

Gastrointestinal complication

Gastrointestinal objections developing from the activation of the immune system because of the use of checkpoint blockers are between the general irAEs. A relation has been monitored in the incident of gastrointestinal irAEs in patients induced with dual CTLA-4/anti-PD-1 therapy and increased survival rates. Gastrointestinal disorders/symptoms occurring from treatment of cancer patients with checkpoint blockers are

noticed including most common is immune colitis, which may manifest as diarrhea, abdominal pain, blood appearance in feces, or the intestine perforation. These signs generally manifest between the 5^{th} to 10^{th} week of immunotherapy (median 6-8 weeks from the treatment initiation), and the symptoms mainly determine after 4 weeks. There have been records of such problems even several months after the discontinuation of treatment. Combined therapy with nivolumab/ipilimumab is recorded to assist to an occurrence of gastrointestinal adverse events (diarrhea, colitis) in nearly 50 % of patients.[56]

Respiratory complication

Respiratory issues in the form of checkpoint blocker pneumonitis are reported in a 2-4 percentage of patients, while severe problems causing to respiratory failure and needing treatment under intensive care unit (ICU) states are unusually special with anti-PD-1 monotherapy. Although, the frequency of such problems is almost doubled in patients trialed with dual therapy for melanoma. It should be remaindered that respiratory failures like shortness of breath and coughing are general, mainly in people being trialed for lung cancer or with metastatic lung disease. The stiffness of these signs can express disease progression, but it can be a signal that several diagnostic measures are compulsory to explore the chances of problems creating from immunotherapy. While factors raising the events of pulmonary issues in the course of immunotherapy, additionally to the presence of neoplastic variations in the lungs, involve prior chest radiotherapy, advanced age, earlier cytostatic therapy, symptomatic pneumonia, or combined therapy.[57]

Rheumatological and musculoskeletal complication

Rheumatological problems are the rarest and investigated in only 5-10 % of patients. Although, they are more often related with treatment by anti-PD-1 antibodies. During treatment, patients can examine rheumatic signs, which often copy those of rheumatic disorders involving rheumatoid arthritis, myositis, vasculitis, sarcoidosis, and lupus. The signs are often unclear and infrequently recorded as different entities. In patients with a prior detection of autoimmune disease, inflammations are noticed during immunotherapy. In cases of restricted sign severity, intra-articular introduce of steroids has been used, and similarly in higher severity glucocorticosteroids have been introduced. Sicca syndrome has also been recorded and investigated in patients after checkpoint blockers. Symptoms occur most often in the first 3 months of treatment, often expressing quickly with a dry mouth. Biopsy of the salivary gland displays symptoms of inflammation, but the representation varies from that in Sjogren's syndrome. Glucocorticosteroids are implemented in the treatment, but signs often continue despite aborted of immunotherapy.[58]

Nephrological complication

Nephrotoxicity is one of the rarest conditions assisted with immunotherapy. In addition, using indicated scales for the evaluation of renal function is hard, because of variations in the parameters estimated (acute kidney injury categorization). Therefore, the lower in eGFR is often hard to examine. Primarily, renal issues were investigated only in patients treating with ipilimumab (3.4 %). Although, these conditions have also been monitored in patients trialed with PD-1/PD-L1 blockers. A higher rate of renal side effects has been reported with dual checkpoint therapy at a frequency of around 5 %. The most general forms of renal irAEs are acute kidney injury, which appears drug-induced tubulointerstitial nephritis, and proteinuria may be shown from 1-8 months after prior treatment. Detained reaction distinguishes drug-induced toxicity. The analysis is most often made in the course of schedule tests earlier to the introduction of consequent doses of immunotherapy. Acute kidney injury indications appear much later than is habitual for the drugs that generally lead to kidney failure.[59]

Cardiovascular complication

Cardiovascular problems linked with the use of checkpoint immunotherapy are as yet highly undetected and rare, but when they do appear, are a critical issue of treatment, often representing a life-threatening crisis. Cardiotoxicity has been detected in the form of myocarditis, pericarditis, Takotsubo syndrome, arrhythmias, and vasculitis. Because a some such cases have been determined in the literature, therefore, the efficacy of appearance, predictors, and treatment are not well evaluated. The examinations to date show that cardiotoxicity can be one of the substantial causes of mortality between irAEs. An investigation evaluating 88 cases showed that irAEs of cardiovascular origin are specified through raised levels of troponins and non-particular variations in the ECG, which concludes the significance of leading coronary angiography between the detection of cardiotoxicity related with immunotherapy. It is preferable that patients should be inspected in cardio-oncology institutes, because prior detection and the use of suitable treatment strategies may help to decrease mortality from these adverse side effects, evaluated at about 50 %.[60]

Hematological complication

Autoimmune hemolytic anemia has been observed in a patient trialed with nivolumab. Several problems involve red blood cell aplasia, neutropenia, thrombocytopenia, hemophilia A, multidysplastic syndrome, fatal anaplastic anemia, and immune thrombocytopenic purpura. Important enhancement was noticed after termination of immunotherapy and administration of glucocorticosteroids.[61]

Dermatological complication

Skin conditions are prior to arise and the most general adverse effects in link with immunotherapy in patients reported with anti-CTLA-4 (45-65 % with ipilimumab) and anti-PD-1/PD-L1 (30-40 % with nivolumab/pembrolizumab). IrAEs that emerged from ipilimumab occurred within 12 weeks of prior treatment. Dual therapy with ipilimumab/nivolumab fallowed in the appearance of adverse events infecting the skin in around 70 % of treated patients, $G_{3/4}$ arising in about 20 % of patients. Dermal toxicity in the case of anti-CTLA-4 and anti-PD-1 antibodies was expressed prior and took a time and more worsen course. Itching was the most fasten observed sign during treatment related with maculopapular rash or with ordinary-looking skin. Even with the most usual side effects, skin lesions are generally of a minor intensity, and issues at the $G_{3/4}$ degree develop in around 3 % of trailed patients. Treatment of severe problems needs dermatological examination and hospitalization. In patients undergoing immunotherapy record skin-related uncertainty possibly experienced through necessary treatment, to eliminate further

feasible causes like several drugs infection or the further situations impact, taking into view common symptoms (fever, lymphadenopathy).[62]

Neurological complication

Analysis of the events of neurological problems is made hard through the appearance of paraneoplastic syndromes in patients trialed for lung cancer. From several investigations, lymphocytic pituitary inflammation was involved in this class of incidents and its impact on hormonal function, and treatment should preferred be involved with endocrine issues. However, the efficiency of irAEs associated to the nervous system is reported at approximately 4 % of patients introduced with ipilimumab and 6 % of patients with anti-PD-1/PD-L1 antibodies. Moreover, combined of these two drugs, the efficacy of symptoms rises to about 12 %. Adverse neurological indications (headache, dizziness, or taste confusions) occur between the 6-8 week of therapy and are comparatively temperate. Neurological disorders in the area of peripheral nervous system dysfunction arise infrequent, but major signs like Guillain-Barre Syndrome, myasthenia gravis, or peripheral polyneuropathy generally need medication with long-term steroid therapy and in resistive to such treatment, immunoglobulins, plasmapheresis, or immunosuppressants (azathioprine) can be implemented, which will commonly need of a neurologist.[63]

Visionary complication

Visionary problems are uncommonly rare and may be noticed in fewer than 1 % of patients. They can arise both in the 1 weeks of therapy and onward. Ocular problems involve uveitis, episcleritis, iritis, and conjunctivitis. Uveitis is a critical issue, which evident itself as visual disability. It is suggestable cases to advise an ophthalmologist to start treatment and too often permanent terminate immunotherapy. Topical compositions may be implemented in the case of common adverse events like dryness. Patients earlier treated with BRAF/MEK blockers, in whom an aggregation of adverse events can be noticed, need a specific alert.[64]

CONCLUSIONS

The cancers treatment with checkpoint blockers has definitely been an important strategy in the area of onco-immunology in modern period. The inhibiting probability of PD-1/PD-L1 checkpoint supplied a chance for obtaining treatment outcomes that could not have been realized with basic chemotherapy. The implementation of checkpoint blockers will continuously rise with the use of fresh symptoms, their introduction at prior stages of cancer therapy will become fairer. New approaches based on ideas employing yet unutilized anticancer treatments combining checkpoint blockers with targeted therapies. With the increasing use of the checkpoint blockers, to be predicted that clinicians will be overlooked ever rising with having to handle the adverse events related with these drugs. Advance medication strategy present new problems for immunologists in several medical areas. They also accredit the require for taking an integrated path to the patient, a concept that is broadly appreciated in onco-immunology.

This is very significant due to the broad difference of organ issues that can influence patients trialed with the diversified implement of immunotherapy. It should be carried in mind that yet critical and life-threatening indications are rare, patients will disclose systemic or organ signs of diverse severity. The base for kind of supervision process is to assist proper patient knowledge and ensure interdisciplinary collaboration and adherence to investigating and therapeutic suggestions. Understanding and alertness of the spectrum of adverse events conducting immunotherapy will permit clinicians to superior capable patients for medication, prevent symptoms, correctly acknowledge, and finally diagnose them. The common indications will be presented to general specialists, as they can occur even after the treatment completion and intermittently rise in line with disease progression. practitioners in different areas will often obtain handovers for patients suffering these kinds of adverse events or will be informed to supplied care in cases needing hospitalization of patients with problems in their area of expertise.

Acknowledgements

The author thankful to Visvesvaraya National Institute of Technology, Nagpur to encouraged for research work. The author also thankful to Faculty of Science, Janata Junior College, Nagbhid to encouraged for research work.

Author Contribution

The author has alone responsible for research work and writing this article.

Funding Source: None

Conflict of interest

The authors declare no conflict of interest.

References

1. Marek, Z. W., Magdalena, M. R., Kamil, K., Maria, G., Barbara, P., Anna, M., *et al*. (2021). Inhibitors of immune checkpoints - PD-1, PD-L1, CTLA-4 - new opportunities for cancer patients and a new challenge for internists and general practitioners. *Cancer Metastasis Reviews*, *40*(4), 949-982.
2. Swann, J. B., & Smyth, M. J. (2007). Immune surveillance of tumors. *Journal of Clinical Investigation*, *117*(5), 1137-1146.
3. Xin, Y. J., Hubbard-Lucey, V. M., & Tang, J. (2019). Immuno-oncology drug development goes global. *Nature Reviews Drug Discovery*, *18*(12), 899-900.
4. Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996). CD28/B7 system of T-cell costimulation. *Annual Review of Immunology*, *14*, 233-258.
5. Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992). Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. *The EMBO Journal*, *11*(11), 3887-3895.
6. Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008). PD-1 and its ligands in tolerance and immunity. *Annual Review of Immunology*, *26*, 677-704.
7. Yamazaki, T., Akiba, H., Iwai, H., Matsuda, H., Aoki, M., Tanno, Y., *et al*. (2002). Expression of programmed death 1 ligands by murine T-cells and APC. *Journal of Immunology*, *169*(10), 5538-5545.
8. Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999). B7-H1, a third member of the B7 family,

costimulates T-cell proliferation and interleukin-10 secretion. *Nature Medicine, 5*(12), 1365-1369.
9. Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., *et al*. (2001). PD-L2 is a second ligand for PD-1 and inhibits T-cell activation. *Nature Immunology, 2*(3), 261-268.
10. Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., *et al*. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. *Journal of Clinical Oncology, 28*(17), 3167-3175.
11. Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., *et al*. (2004). Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. *Proceedings of the National Academy of Sciences of the United States of America, 101*(46), 17174-17179.
12. Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., *et al*. (2010). Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. *Cancer, 116*(7), 1757-1766.
13. Zeng, Z., Shi, F., Zhou, L., Zhang, M. N., Chen, Y., Chang, X. J., *et al*. (2011). Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. *PLoS One, 6*(9), e23621.
14. Gao, Q., Wang, X. Y., Qiu, S. J., Yamato, I., Sho, M., Nakajima, Y., *et al*. (2009). Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. *Clinical Cancer Research, 15*(15), 971-979.
15. Mu, C. Y., Huang, J. A., Chen, Y., Chen, C., & Zhang, X. G. (2011). High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. *Medical Oncology, 28*(3), 682-688.
16. Zhang, Y., Huang, S., Gong, D., Qin, Y., & Shen, Q. (2010). Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T-lymphocytes in human non-small cell lung cancer. *Cellular & Molecular Immunology, 7*(5), 389-395.
17. Zhou, Q., Xiao, H., Liu, Y., Peng, Y., Hong, Y., Yagita, H., *et al*. (2010). Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T-cells and enhances the antitumor efficacy of lentivector immunization. *Journal of Immunology, 185*(9), 5082-5092.
18. Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., *et al*. (2007). Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. *Clinical Cancer Research, 13*(7), 2151-2157.
19. Iwai, Y., Terawaki, S., & Honjo, T. (2005). PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T-cells. *International Immunology, 17*(2), 133-144.
20. Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T-cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. *Proceedings of the National Academy of Sciences of the United States of America, 107*(9), 4275-4280.
21. Larkin, J., Minor, D., D'Angelo, S., Neyns, B., Smylie, M., Miller Jr., W. H., *et al*. (2018). Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in Check Mate 037: a randomized, controlled, open-label phase III trial. *Journal of Clinical Oncology, 36*(4), 383-390.
22. Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L., *et al*. (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *The New England Journal of Medicine, 377*, 1345-1356.
23. Weber, J., Mandala, M., Del Vecchio, M., Gogas, H. J., Arance, A. M., *et al*. (2017). Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. *The New England Journal of Medicine, 377*, 1824-1835.
24. Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E., Poddubskaya, E., *et al*. (2015). Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. *The New England Journal of Medicine, 373*(2), 123-135.
25. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., *et al*. (2015). Nivolumab versus docetaxel in advanced non-squamous non-small-cell lung cancer. *The New England Journal of Medicine, 373*(17), 1627-1639.
26. Ferris, R. L., Blumenschein Jr., G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., *et al*. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. *The New England Journal of Medicine, 375*(19), 1856-1867.
27. Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., *et al*. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (Check Mate 275): A multicentre, single-arm, phase 2 trial. *The Lancet Oncology, 18*, 312-322.
28. Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., *et al*. (2015). Nivolumab versus everolimus in advanced renal-cell carcinoma. *The New England Journal of Medicine, 373*(19), 1803-1813.
29. El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., *et al*. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (Check Mate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. *The Lancet, 389*, 2492-2502.
30. Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H. J., Morse, M. A., *et al*. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (Check Mate 142):

An open-label, multicentre, phase 2 study. *The Lancet Oncology, 18*(9), 1182-1191.
31. Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., *et al*. (2015). Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. *Journal of Clinical Oncology, 33*(34), 4015-4022.
32. Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., *et al*. (2015). PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. *The New England Journal of Medicine, 372*(4), 311-319.
33. Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., *et al*. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. *The New England Journal of Medicine, 372*, 2521-2532.
34. Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., *et al*. (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (keynote-002): A randomised, controlled, phase 2 trial. *The Lancet Oncology, 16*(8), 908-918.
35. Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., *et al*. (2016). Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. *The New England Journal of Medicine, 375*(19), 1823-1833.
36. Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., *et al*. (2018). Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. *The New England Journal of Medicine, 378*(22), 2078-2092.
37. Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J. L., Fong, L., *et al*. (2017). Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *New England Journal of Medicine, 376*(11), 1015-1026.
38. Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., *et al*. (2017). First-line pembrolizumab in cisplatin ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (Keynote-052): a multicentre, single-arm, phase 2 study. *The Lancet Oncology, 18*(11), 1483-1492.
39. Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., *et al*. (2014). Safety and activity of PD-1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. *The Lancet Oncology, 15*(1), 69-77.
40. Armand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y. B., *et al*. (2013). Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. *Journal of Clinical Oncology, 31*(33), 4199-4206.
41. Camicia, R., Winkler, H. C., Hassa, P. O. (2015). Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: A comprehensive review. *Molecular Cancer, 14*, 207.
42. Mahoney, K. M., Freeman, G. J., McDermott, D. F. (2015). The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. *Clinical Therapeutics, 37*(4), 764-782.
43. Fried, I., Lossos, A., Ben-Arush, M., Dvir, R., Toledano, H., Ben-Barak, A. (2018). Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma. *Journal of Neuro-Oncology, 136*(1), 189-195.
44. Rischin, D., Migden, M. R., Lim, A. M., Schmults, C. D., Khushalani, N. I., Hughes, B. G. M., *et al*. (2020). Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: Primary analysis of fixed-dosing, long-term outcome of weight-based dosing. *Journal for Immunotherapy of Cancer, 8*(1), e000775.
45. Migden, M. R., Rischin, D., Schmults, C. D., Guminski, A., Hauschild, A., Lewis, K. D., *et al*. (2018). PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. *The New England Journal of Medicine, 379*(4), 341-351.
46. Lee, A., Duggan, S., Deeks, E. D. (2020). Cemiplimab: A review in advanced cutaneous squamous cell carcinoma. *Adis Drug Reviews, 80*(8), 813-819.
47. Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., *et al*. (2017). Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial. *Lancet, 389*(10064), 67-76).
48. Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., *et al*. (2016). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. *Lancet, 389*(10066), 255-265).
49. Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., *et al*. (2018). Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. *New England Journal of Medicine, 379*(24), 2342-2350).
50. Boyerinas, B., Jochems, C., Fantini, M., Heery, C. R., Gulley, J. L., Tsang, K. Y., *et al*. (2015). Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-1 antibody avelumab (MSB0010718C) on Human Tumor Cells. *Cancer Immunology Research, 3*(10), 1148-1157)
51. Collins, J. M., & Gulley, J. L. (2019). Product review: avelumab, an anti-PD-L1 antibody. *Human Vaccines & Immunotherapeutics, 15*(4), 891-908.
52. Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., *et al*. (2019). Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. *The New England Journal of Medicine, 380*(12), 1103-1115.
53. Wei, S. C., Duffy, C. R., & Allison, J. P. (2018). Fundamental mechanisms of immune checkpoint blockade therapy. *Cancer Discovery, 8*(9), 1069-1086.

54. Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., *et al*. (2015). Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *The New England Journal of Medicine*, *372*, 2006-2017.
55. Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018). Immune-related adverse events associated with immune checkpoint blockade. *The New England Journal of Medicine*, *378*(2), 158-168.
56. Cramer, P., & Bresalier, R. S. (2017). Gastrointestinal and hepatic complications of immune checkpoint inhibitors. *Current Gastroenterology Reports*, *19*(1), 3.
57. Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., *et al*. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. *The New England Journal of Medicine*, *372*, 2018-2028.
58. Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2017). Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature. *Arthritis Care and Research*, *69*(11), 1751-1763.
59. Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., *et al*. (2016). Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. *Kidney International*, *90*(3), 638-647.
60. Hu, J. R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., *et al*. (2019). Cardiovascular toxicities associated with immune checkpoint inhibitors. *Cardiovascular Research*, *115*(5), 854-868).
61. Boutros, C., Tarhini, A., Routier, E., Lambotte, O., Ladurie, F. L., Carbonnel, F., *et al*. (2016). Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. *Clinical Oncology*, *13*, 473-486.
62. Sibaud, V. (2018). Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy. *American Journal of Clinical Dermatology*, *19*(3), 345-361.
63. Johnson, D. B., Wallender, E. K., Cohen, D. N., Likhari, S. S., Zwerner, J. P., Powers, J. G., *et al*. (2013). Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. *Cancer Immunology Research*, *1*(6), 373-377.
64. Dalvin, L. A., Shields, C. L., Orloff, M., Sato, T., & Shields, J. A. (2018). Checkpoint inhibitor immune therapy: Systemic indications and ophthalmic side effects. *The Journal of Retinal and Vitreous Diseases*, *38*(6), 1063-1078).

How to cite this article:

Ashish Shivram Ramteke. (2024). Immune Checkpoint Blockers: Challenges, Opportunities and Strategies for Cancer Patients. *International Journal of Current Advanced Research.*13(03), pp.2959-2969.

****